NMPA Registration: Getting a Medical Device into China

Introduction

NMPA registration is lost long before the dossier reaches the Center for Medical Device Evaluation. It is lost when a manufacturer assumes that a CE certificate tells China what class the device is, when the Chinese agent is chosen on price as if it were a mailbox, and when nobody in the company has ever written a document China treats as legally binding but Europe never asked for: the product technical requirements. Every one of those decisions is made in the first weeks of a China project, and every one of them surfaces a year later as a deficiency letter with a twelve-month deadline.

This guide is written for manufacturers who already hold EU or US approval and are now looking at China. It reads the two instruments that actually govern the route — State Council Order No. 739 and the Provisions for Medical Device Registration and Filing, SAMR Decree No. 47 — and translates them into what a regulatory team has to do. Readers who have been through ANVISA registration in Brazil will recognise the pattern, and the EU MDR technical documentation you already have is the starting material, not the answer.

The article covers the legal framework, classification, what must be in place before you file, the seven-part dossier, product technical requirements and type testing, clinical evaluation, the quality management system inspection, the statutory review clock, life after approval, and the six gaps that stall foreign registrations.

Table of Contents

• Why NMPA registration is decided before the dossier is written
• China classifies the device again, and the CE class does not travel
• What a foreign manufacturer must have in place before filing
• The Chinese agent is a legal person with liabilities, not a mailbox
• Home-country approval comes first, with one exception
• Everything is submitted in Chinese, and the originals go with it
• The seven-part registration dossier, read against your EU file
• Product technical requirements: the document Europe never asked you for
• What the product technical requirements must contain
• Type testing against them: self-test or accredited laboratory
• Clinical evaluation in China: exemption, predicate data or a trial
• The quality system is inspected through the dossier
• The statutory clock, and the twelve months that decide the outcome
• After approval: changes, renewal and post-market duties
• Six gaps that stall foreign NMPA registrations
• Frequently asked questions
• Conclusions

Why NMPA registration is decided before the dossier is written

China regulates medical devices through a short chain of instruments, and a foreign manufacturer needs to know which layer it is reading. At the top sits the Regulations on the Supervision and Administration of Medical Devices, State Council Order No. 739, which came into force on 1 June 2021. Order 739 sets the architecture: risk classes, filing versus registration, the content of a submission, clinical evaluation, production, distribution, adverse events and penalties. Below it, the Provisions for Medical Device Registration and Filing (SAMR Decree No. 47, in force since 1 October 2021) turn that architecture into procedure — who reviews what, which documents, which deadlines and which grounds for rejection. Order 47 explicitly excludes in vitro diagnostic reagents, which have their own registration provisions (Order 47, Article 121), so everything below concerns medical devices only.

The institutional map matters because each body has a defined job. The National Medical Products Administration (NMPA) administers registration and filing nationwide and approves imported Class II and Class III devices (Order 47, Article 4). Its Center for Medical Device Evaluation (CMDE) performs the technical evaluation of those applications and of clinical trial applications (Article 5). Other technical institutions — among them the National Institutes for Food and Drug Control and the Center for Food and Drug Inspection (CFDI) — handle standards, classification and definition, testing and inspection. Provincial drug regulatory departments review domestic Class II devices and inspect domestic manufacturers, but for an importer they matter mainly because they supervise the agent and the clinical trial sites.

The legal definition is broad enough to catch most products that a European manufacturer sells as a device. Order 739, Article 103 covers instruments, equipment, appliances, in vitro diagnostic reagents and calibrators, materials and similar items, "including the required computer software", whose effect is not achieved by pharmacological, immunological or metabolic means, or where such means play only a supporting role. Software and wellness-adjacent products still need a deliberate determination; the definition does not resolve them by itself.

What follows from this structure is the thesis of this article. China does not review a dossier in the abstract; it reviews a product description fixed at a specific class, defended by a specific set of measurable indicators, tested against those indicators, and represented by a specific Chinese legal person. Get those four inputs wrong and no amount of dossier quality recovers the project. Figure 1 shows the complete route for an imported device.

China classifies the device again, and the CE class does not travel

Order 739, Article 6 creates three risk classes. Class I devices are low risk and routine management is enough to ensure their safety and effectiveness. Class II devices are moderate risk and require strict control. Class III devices are higher risk and require special measures. The factors that determine the class are the intended use, the structural characteristics and the method of use, and NMPA owns both the classification rules and the classification catalogue, which it is required to adjust as risk understanding changes.

The class decides the route. Class I devices are filed; Class II and Class III devices are registered (Order 739, Article 13; Order 47, Article 8). For an imported device, NMPA is the authority in every case: it receives the filing for Class I and reviews the registration for Class II and Class III. A domestic Chinese competitor goes to the city-level regulator for Class I and to the provincial regulator for Class II. That asymmetry explains a common surprise — a Chinese company can obtain a Class II certificate through its province while the imported equivalent is reviewed nationally by CMDE.

The three classes look familiar to anyone who works under the EU MDR or with the FDA, and that is exactly the trap. China's classification rules work on their own logic, and several principles push products upward regardless of how they are classified elsewhere. Devices supplied sterile, devices with a measuring function and devices intended for treatment cannot fall below Class II; absorbable devices are Class III; a combination product whose principal action is that of a device is managed as Class III; and where two classifications could apply, the higher one wins. A sterile single-use accessory that is Class I in a European file can therefore be a Class II registration in China, with a full technical evaluation behind it.

The catalogue is not static either. NMPA continuously issues classification determinations for individual product types and adjusts catalogue entries, and in 2026 it formalised a procedure for dynamic adjustment of the catalogue together with transition rules for products whose management category changes. A class that was correct when a competitor registered five years ago is a starting hypothesis, not evidence.

For a genuinely new product that is not in the catalogue, the law offers two routes. The applicant can apply directly for registration as a Class III device, in which case NMPA determines the class on the basis of risk; or it can determine the class itself under the classification rules and apply to NMPA for class confirmation before filing or registering (Order 739, Article 23; Order 47, Article 64). Order 739 gives NMPA 20 working days from acceptance to confirm the category. For an innovative device, asking first is almost always cheaper than discovering the answer at the end of a Class III review.

What a foreign manufacturer must have in place before filing

Three conditions sit outside the technical file entirely, and each of them can stop an application before CMDE reads a single test report. They are where foreign manufacturers lose the first six months of a China project.

The Chinese agent is a legal person with liabilities, not a mailbox

An overseas applicant or filing entity must designate a domestic enterprise legal person as its agent to carry out the registration or filing (Order 47, Article 14). The agent is not a forwarding address. It must assist the registrant in fulfilling the obligations in Order 739, Article 20 — maintaining a quality management system suited to the product, running post-market research and risk control plans, monitoring adverse events and conducting re-evaluation, and operating traceability and recall — and it must help the overseas registrant carry out the corresponding legal liabilities.

The penalty provisions show how seriously China takes the role. Under Order 739, Article 98, an agent that fails to perform its obligations faces correction orders, a warning and fines, and in serious cases its legal representative and responsible persons can be barred from the device business for five years. The provision then turns to the manufacturer: an overseas registrant that refuses to carry out an administrative penalty decision is prohibited from importing medical devices for ten years. The agent's name and contact details also go on the Chinese instructions for use (Order 739, Article 57), and the provincial regulator where the agent sits supervises it routinely (Order 47, Article 102).

Choose the agent as you would choose a PRRC or an EU authorised representative under a mandate you might one day have to defend in front of an authority: on competence and on its ability to run vigilance and recalls in Chinese, not on the annual fee.

Home-country approval comes first, with one exception

An imported device must be marketed at home before China will look at it. The applicant submits the marketing certificate issued by the competent authority of the country or region where the applicant is registered or where the manufacturing site is located (Order 47, Article 18; Order 739, Article 16). If the product is not regulated as a medical device in that country, the applicant provides proof of that status together with evidence that it may be marketed there. The single exception is an innovative medical device that has not yet been marketed in its home country, for which no home-country certificate is required.

The practical consequence is sequencing. China is not a first-market strategy for an established foreign manufacturer unless the device qualifies as innovative, and the scope of the home-country approval — models, intended use, manufacturing site — should match the scope you intend to register in China. A Chinese application that is wider than the home approval invites questions the applicant cannot answer.

Everything is submitted in Chinese, and the originals go with it

Registration and filing documents are in Chinese; where they are translated from a foreign language, the original documents are submitted at the same time (Order 47, Article 17). The applicant is responsible for the authenticity of everything it submits, and unpublished literature can only be cited with proof of the owner's permission. Translation is therefore not an administrative step at the end. The Chinese text is the legally binding version of your product technical requirements and your labelling, and discrepancies between it and the original are treated as dossier defects.

Order 739, Article 57 states that imported devices must carry Chinese instructions for use and Chinese labels, and the instructions for use must state the place of origin and the name, address and contact details of the agent. A device without compliant Chinese labelling is not imported at all — so the label artwork belongs in the registration plan, not in the launch plan.

The seven-part registration dossier, read against your EU file

Order 47, Article 52 lists what a registration application contains, and Order 739, Article 14 repeats the same list for both filing and registration. There are seven elements: product risk analysis data; product technical requirements; the product test report; clinical evaluation materials; the instructions for use and label samples; quality management system documents relating to product development and manufacturing; and any other materials needed to demonstrate safety and effectiveness. The submission is made online, and Article 52 is explicit about timing: you apply once the safety and effectiveness studies are complete and you are ready to receive a quality system inspection.

Most of this material exists in a well-built EU file. What changes is the form it has to take and the legal weight each element carries in China. The table maps the seven elements to their nearest EU MDR counterpart and to the work that remains.

Two further provisions shape how a dossier is organised. Registration units are defined by technical mechanism, structural composition, performance indicators and scope of application (Order 47, Article 111), which decides how many models can share one certificate. And an applicant may reference a registered device master file with the owner's authorisation (Article 114), which is how a component or material supplier's confidential data can support your application without being handed over to you.

The non-clinical evidence deserves its own planning line. Article 28 lists chemical and physical properties, electrical safety, radiation safety, software, biological properties, biological material safety, disinfection and sterilisation, animal studies and stability, each reported as overview, protocol and report. If your biocompatibility evaluation or your IEC 62304 software documentation exists only as a summary in a technical file, the underlying protocols have to be retrieved and translated.

Product technical requirements: the document Europe never asked you for

If one document decides whether a European team finds China difficult, it is this one. The product technical requirements are not a datasheet, not a design input specification and not a summary of harmonised standards. They are a short, legally binding statement of the performance and safety indicators the finished device must meet, each paired with a method that can objectively determine it (Order 47, Article 26). Once approved, they are issued as an attachment to the registration certificate (Article 58), every device produced must comply with them (Article 26), and the manufacturer must release product against them (Order 739, Article 35). Change them and you are in change registration (Order 47, Article 79).

What the product technical requirements must contain

Article 26 asks for functional and safety indicators and test methods that can be objectively determined for the finished device. Article 29 adds that indicators and methods determined in the non-clinical studies must suit the intended use conditions, that test samples must be representative and typical, and that methodological validation and statistical analysis are performed where necessary. Every indicator therefore needs a traceable origin in a study, and every method needs to be one a third party could repeat.

Mandatory standards set the floor. Devices must conform to applicable mandatory national standards, or to mandatory industry standards where there is no national one (Order 739, Article 7). Where a mandatory standard does not fit the product's structure, intended use or method of use, the applicant files a statement of non-applicability with supporting evidence (Order 47, Article 19). Recommended standards are encouraged where no mandatory standard exists. A European team that builds its file on EN ISO and EN IEC editions needs to check the corresponding Chinese standards and their editions, not assume equivalence.

Write the indicators narrowly. Every value you put in this document is a value you must reproduce in every batch for five years and defend in every change. Marketing specifications, typical values and parameters that do not bear on safety or performance do not belong in it.

Type testing against them: self-test or accredited laboratory

Testing is performed according to the product technical requirements, and only a device that passes can proceed to clinical trial, registration or filing (Order 47, Article 30). The samples must represent the safety and effectiveness of the product and be produced under GMP for Medical Devices (Article 31). Since the 2021 reform, the report can be either the applicant's own self-test report or a report from a qualified medical device testing institution (Article 32; Order 739, Article 14).

The self-test option is real, but it moves the scrutiny rather than removing it. Where a self-test report is submitted, the quality system inspection focuses on the testing capability of whoever performed the tests and on the results (Order 47, Article 49). An applicant without documented test methods, calibrated equipment, trained personnel and complete raw data is better served by a qualified laboratory.

Clinical evaluation in China: exemption, predicate data or a trial

Clinical evaluation is the default for every registration and filing (Order 47, Article 33), and the same article draws a distinction that matters for Class I: the evaluation is conducted for filings as well, but only registration applications have to submit clinical evaluation materials. Two circumstances allow exemption altogether (Article 34; Order 739, Article 24). The first is a device whose working mechanism is clear, whose design is finalised and manufacturing process mature, where predicate devices have been in clinical use for years with no record of serious adverse events and the conventional use is unchanged. The second is a device whose safety and effectiveness can be proven by non-clinical evaluation. NMPA formulates, adjusts and publishes the catalogue of exempted devices, and the first check in any China project is whether your device type is on it.

Outside the exemption, Article 35 offers two routes: a clinical trial, or analysis of clinical literature and clinical data of predicate devices. Where existing literature and data are insufficient to confirm safety and effectiveness, a trial is required. A predicate-based evaluation must compare the device with the predicate and provide scientific evidence for every difference (Article 36). It is the Chinese cousin of an equivalence argument, and it fails for the same reason: a difference that is described but not justified with data.

When a trial is needed, it runs under Chinese GCP in clinical trial institutions that have been filed, and the sponsor files the trial with the provincial regulator before it starts (Article 37). Class III trials that pose high risk to the human body need NMPA approval first, and NMPA publishes the catalogue of those device types (Article 38). Such trials can only be conducted in qualified tertiary A hospitals. CMDE decides within 60 working days of acceptance, and silence counts as approval (Article 40; Order 739, Article 27). An approved trial must enrol: if no subject signs informed consent within three years of approval, the approval lapses (Order 47, Article 45).

Class and clinical trial are separate decisions. A Class III device does not automatically need a Chinese trial, and the trial-approval requirement applies only to the catalogue of high-risk Class III devices, not to every Class III product. Plan the clinical route from the exemption catalogue and the quality of your predicate comparison, not from the class alone.

The predicate route rewards manufacturers whose existing clinical evaluation is already rigorous. If your EU MDR clinical evaluation documents the state of the art, the comparator devices and the gap analysis properly, most of the reasoning transfers. If it relies on a thin equivalence claim, China will expose it as quickly as a Notified Body would.

The quality system is inspected through the dossier

In Europe the quality system is certified separately and the technical documentation is assessed against it. In China the quality system is part of the product application. The applicant submits QMS materials relating to development and manufacturing with the registration (Order 47, Article 47), and the regulator reviews the applicant's ability to ensure quality management as part of the registration decision (Order 739, Article 17). Where the reviewing authority considers it necessary, it organises a quality system inspection and may access original data.

For imported Class II and Class III devices, CMDE notifies CFDI to carry out the inspection when it considers one necessary (Order 47, Article 51). Article 51 directs CFDI to inspect according to the relevant requirements, and the criteria Article 49 sets for registration inspections are GMP for Medical Devices, with a focus on design and development, production management and quality control. It also checks the authenticity of the samples used for testing and clinical trials by reviewing the design and manufacturing records behind them. For provincial inspections Article 50 allows document review or an on-site visit, and directs the inspectors to avoid repeated inspection where manufacturing conditions are unchanged from a previously reviewed product.

The point most foreign teams miss is the authenticity check. The samples that went to the test laboratory and into the clinical evaluation have to be traceable to real design history and production records. A sample built by an engineering team in a pilot line, outside the controlled process, is a finding waiting to happen. A quality system already structured on ISO 13485 and aligned with MDSAP audit practice is the right foundation, but the records behind the registration samples need to be assembled deliberately.

The statutory clock, and the twelve months that decide the outcome

Order 47 sets maximum time limits, mainly in Chapter VII, and Article 99 states that all of them are counted in working days. The figures below apply to imported devices reviewed by NMPA.

Two features of the clock matter more than the headline numbers. First, time does not run while the file is with the applicant. Article 98 excludes the time spent preparing supplementary materials or remediation, delays attributable to the applicant, external expert consultation, joint evaluation with the drug evaluation centre for combination products, suspension of review and the quality system inspection itself. The statutory limits describe the regulator's share of the elapsed time, not your launch date.

Second, the deficiency process is one-shot. CMDE issues all supplementary requests in a single notification, and the applicant has one year to answer all of them in a single delivery (Order 47, Article 54). Miss the year, or fail to answer, and the technical evaluation is terminated and the application rejected. An applicant who disagrees with a request can submit written reasons and technical evidence (Article 54), and if the evaluation heads towards rejection the applicant has 15 working days to object, limited to the original application and materials (Article 57). The year looks generous; it rarely is when the request involves new testing, a revised product technical requirements document and a translated reply.

NMPA also runs accelerated routes. Innovative devices that meet the patent, maturity and novelty criteria of Article 68 enter a special procedure with dedicated reviewers and early technical communication (Article 70); priority review applies to defined clinical needs under Article 73; and emergency procedures exist for public health emergencies (Article 76). Conditional approval is possible for rare diseases, serious life-threatening conditions without effective treatment and public health emergencies, with post-market obligations written into the certificate (Article 61). The innovative route turns on a Chinese invention patent for the core technology, which limits its practical reach for most foreign manufacturers.

After approval: changes, renewal and post-market duties

The registration certificate is valid for five years (Order 47, Article 58; Order 739, Article 22), with the approved product technical requirements attached. Its number tells a reader exactly what it is: Article 115 sets the format, in which an imported Class II or Class III device carries the character for "national" as the issuing authority and the character for "import" as the registration form, followed by the year of first registration, the class, the product classification code and a serial number. Imported Class I filings follow their own national filing-number format under Article 116, and Order 739, Article 39 requires the registration certificate number on the labels of Class II and Class III devices.

Changes split into two tracks under Order 47, Article 79. Substantial changes to design, raw materials, manufacturing process, scope of application or method of use that may affect safety and effectiveness require change registration with the original authority. For an imported device, the items requiring change registration include the product name, model, specification, structure and composition, scope of application, product technical requirements and the address of the manufacturing site. Changes to the name and address of the registrant or the agent are filed within 30 working days. Everything else is managed inside the quality system and reported as required. A change control procedure written only for the EU MDR will not route these decisions correctly; it needs a China column.

Renewal is filed six months before expiry (Order 47, Article 82). If the authority does not decide in time, the renewal is deemed approved, but three circumstances block it outright: a late application, a device that cannot meet a newly implemented mandatory standard, and a conditionally approved device that has not completed its obligations (Article 83). The second ground is the one to monitor, because it turns a standards revision in China into a regulatory deadline for your design team.

The post-market obligations mirror the European system without copying it. Order 739, Article 20 requires the registrant to run a quality system, post-market research and risk control plans, adverse event monitoring and re-evaluation, and traceability and recall, with the agent assisting. Article 66 requires the registrant to re-evaluate a marketed device when scientific understanding of its safety and effectiveness changes or when adverse event results indicate a possible defect, and to apply for cancellation of the certificate if safety and effectiveness can no longer be assured. Distribution is regulated too: Chinese companies trading Class II devices file with the city-level regulator, and those trading Class III devices need a business licence valid for five years (Order 739, Articles 41 and 42). Your importer's licences are part of your market access, and a post-market surveillance system designed for Europe needs a Chinese reporting route built into it.

Six gaps that stall foreign NMPA registrations

The same weaknesses recur across foreign applications, and none of them is a scientific problem. Each one is a planning decision made without reading the Chinese instruments. Figure 4 sets them out with the fix that prevents each.

The pattern behind the six is consistent. Manufacturers treat China as a translation exercise applied to a European file, when it is a separate legal construct with its own binding documents: a class confirmed under Chinese rules, product technical requirements that become part of the certificate, a test report against those requirements, records that prove the test samples are real, and a Chinese legal person accountable for all of it. Build those five elements first and the dossier becomes an assembly task. Leave them to the end and the deficiency letter will build them for you, on CMDE's timetable.

Frequently asked questions

How long does NMPA registration take?

The statutory technical evaluation limit is 60 working days for Class II and 90 working days for Class III, plus 60 working days after supplementary materials, 20 working days for the decision and 10 for the certificate. Time spent by the applicant on supplementary materials, testing remediation and the quality system inspection is not counted, and the applicant has up to one year to answer a deficiency notice, so real timelines are much longer than the statutory figures.

Do I need a clinical trial in China for NMPA registration?

Not necessarily. Devices on NMPA's exemption catalogue need no clinical evaluation materials, and others can be supported by analysis of clinical literature and predicate device data. A clinical trial is required when existing data are insufficient. Only Class III devices on NMPA's high-risk catalogue need trial approval from NMPA before the trial starts, and those trials must run in tertiary A hospitals.

Can a foreign manufacturer apply for NMPA registration without a Chinese agent?

No. An overseas applicant must designate a domestic enterprise legal person as its agent to carry out registration or filing. The agent assists with quality management, adverse event monitoring, traceability and recall, appears on the Chinese instructions for use, and is supervised by its provincial regulator. Penalties for agents that fail their obligations include fines and bans on the responsible persons.

Does a device have to be approved in its home country before NMPA registration?

Yes, as a rule. An imported device application must include the marketing certificate issued by the competent authority of the country where the applicant is registered or where the device is manufactured. If the product is not regulated as a device there, proof of that status and of permission to market it is required. Innovative devices not yet marketed in their home country are exempt from this requirement.

How long is an NMPA registration certificate valid?

Five years. The renewal application must be filed six months before expiry. If the authority does not decide in time, renewal is deemed approved, but it is refused if the application is late, if the device cannot meet a newly implemented mandatory standard, or if a conditionally approved device has not completed its obligations.

What is the difference between NMPA filing and registration?

Class I devices are filed: the filing entity submits the documents, the authority records them and publishes the filing information. Class II and Class III devices are registered: the regulator evaluates safety, effectiveness and quality management and issues a registration certificate with the approved product technical requirements attached. For imported devices, NMPA handles both.

Can I use my own test reports for NMPA registration?

Yes. Since the 2021 reform the test report may be the applicant's self-test report or a report from a qualified medical device testing institution. Testing must be performed against the product technical requirements on representative samples made under GMP, and where a self-test report is submitted the quality system inspection focuses on the applicant's testing capability and results.

Does NMPA inspect foreign manufacturing sites?

It can. For imported Class II and Class III devices, CMDE notifies the Center for Food and Drug Inspection to carry out a quality system inspection when it considers one necessary during technical evaluation. The inspection follows GMP for Medical Devices and checks that the samples used for testing and clinical evaluation are traceable to genuine design and manufacturing records.

Conclusions

China rewards manufacturers who treat it as its own regulatory system and punishes those who treat it as a translation of Europe. The decisions that determine the outcome are made at the start: confirm the class under Chinese rules, appoint an agent you would trust with a recall, check the exemption catalogue before planning clinical work, and write product technical requirements narrow enough to meet in every batch for five years.

The rest is discipline. Assemble the deficiency reply as one delivery well inside the year, keep the records behind your test samples inspection-ready, give your change control procedure a China column, and calendar the renewal six months before expiry. A registrant that does those things finds NMPA demanding but predictable.

The EU MDR Technical Documentation Kit on MD Regulatory gives you the structured source file that the Chinese risk analysis, test evidence and clinical evaluation are built from, and the ISO 13485 Documentation Kit covers the quality system that the NMPA inspection examines.

Related articles

• ISO 14971 Risk Management for Medical Devices
• Biocompatibility Testing for Medical Devices

Official source: the English texts of Order 739 and SAMR Decree No. 47 are published by the National Medical Products Administration. In case of any difference in interpretation, the Chinese version prevails.